Biotechnology | COVID-19 | NIH | Pharmaceutical | Vaccine
SARS-CoV-2 infection weakens immune-cell response to vaccination
On Mar. 20, 2023, National Institutes of Health (NIH) scientists announced that the magnitude and quality of a…
-
-
FDA authorized bivalent Pfizer-BioNTech COVID-19 vaccine as booster dose for certain children 6 months through 4 years of age
On Mar. 14, 2023, the U.S. Food and Drug Administration (FDA) amended the emergency use authorization (EUA) of…
-
Pfizer and BioNTech submitted for U.S. EUA of Omicron BA.4/BA.5-adapted bivalent COVID-19 booster in children under 5 years
On Mar. 1, 2023, BioNTech and Pfizer announced that they had submitted an application to the U.S. Food…
-
Moderna to provide free COVID-19 vaccines after U.S. public health emergency ends
On Feb. 15, 2023, Moderna announced it will continue to offer its COVID-19 vaccines for free, even after…
-
Pfizer and BioNTech submit application to U.S. FDA for EUA of Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in children under 5 years
On Dec. 5, 2022, Pfizer and BioNTech announced that the companies had submitted an application to the U.S….
-
Novavax announced expanded approval of Nuvaxovid COVID-19 vaccine for adolescents aged 12 through 17 in Japan
On Jul. 26, 2022, Novavax announced that Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine received expanded manufacturing and marketing approval from…
-
Novavax Nuvaxovid COVID-19 vaccine granted provisional registration in Australia for use in adolescents aged 12 through 17
On Jul. 26, 2022, Novavax announced that the Australian Therapeutic Goods Agency had granted expanded approval for provisional…
-
Biotechnology | Cartoons - Original | COVID-19 | Diagnostics | Medicine | NIH | Non-Profit Research | Pharmaceutical | Therapeutics | U.S. Congress | Vaccine
COVID-19 Vacations Redux
COVID-19 Vacations Redux iIlustrates once again the pits and perils vacation travelers face as they begin their Summer…
-
U.S. FDA granted EUA for Novavax COVID-19 vaccine, adjuvanted for individuals aged 18 and over
On Jul. 13, 2022, Novavax announced that its COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) had received emergency use authorization from…
-
U.S. Government secured 3.2 million doses of Novavax COVID-19 vaccine
On Jul. 11, 2022, Novavax announced an agreement with the U.S. Department of Health and Human Services (HHS),…
-
COVID-19 | Diagnostics | Infectious Disease | NIH | Therapeutics | U.S. Congress | Vaccine
COVID-19 was third leading cause of death in the United States in both 2020 and 2021
On Jul. 5, 2022, the National Institutes of Health and National Cancer Institute announced COVID-19 was the third…
-
Biotechnology | Cartoons - Original | CDC | COVID-19 | Diagnostics | FDA | Infectious Disease | Medicine | Neurology | NIH | Non-Profit Research | Olfactory | Pharmaceutical | Therapeutics | U.S. Congress | Vaccine
COVID-19 Wheel of Fortune
Play the COVID-19 Wheel of Fortune and see how lucky you are! You have two wheels to choose…
-
US Billionaire Launched New Generation Vaccine Manufacturing Plant in South Africa Based on Cancer Immunotherapy
On Jan. 19, 2022, South African-born U.S. biotech billionaire Patrick Soon-Shiong launched a vaccine manufacturing plant in the…
-
Food allergy associated with lower risk of SARS-CoV-2 infection
On Jun. 1, 2022, the U.S. National Institutes of Health (NIH) announced that an NIH funded study had…
-
Computer model predicted dominant SARS-CoV-2 variants
On May 24, 2022, scientists at the Broad Institute of MIT and Harvard and the University of Massachusetts…
-
Novavax filed in the EU for expanded conditional Marketing Authorization of COVID-19 vaccine as booster in individuals aged 18 and over
On May 20, 2022, Novavax announced the submission of a request to the European Medicines Agency (EMA) to…
-
NIH announced antiviral drug development awards
On May 18, 2022, the U.S. National Institutes of Health announced it had awarded approximately $577 million to…
-
Study found ‘natural immunity’ from Omicron weak and limited
On May 18, 2022, researchers at Gladstone Institutes and UC San Francisco (UCSF) reported that unvaccinated people, infection…
-
InteliSwab COVID-19 rapid test validated to detect Omicron BA.2, BA.2.12.1, BA.3 and BA.5 subvariants
On May 17, 2022, OraSure Technologies announced that its InteliSwab COVID-19 rapid tests detect the Omicron BA.2, BA.2.12.1,…
-
KPWHRI report supported value of COVID-19 drugs
On May 11, 2022, Kaiser Permanente Washington Health Research Institute reported that new treatments for people at high…
-
WHO reported 14.9 million excess deaths associated with the COVID-19 pandemic in 2020 and 2021
On May 5, 2022, the World Health Organization (WHO) reported estimates that show the full death toll associated…
-
USDA issued a conditional license for mink Coronavirus Vaccine
On Apr. 27, 2022, the U.S. Department of Agriculture’s Animal and Plant Health Inspection Service announced it had…
-
WHO recommended Paxlovid for high-risk COVID patients
On Apr. 22, 2022, the World Health Organization (WHO) made a strong recommendation for nirmatrelvir and ritonavir, sold…
-
Codiak announced new preclinical data supporting development of broadly protective pan beta-Coronavirus vaccine
On Apr. 20, 2022, Codiak BioSciences announced announc a Non-Clinical Evaluation Agreement (NCEA) with the National Institute of…
-
Novavax announced approval of Nuvaxovid COVID-19 vaccine for primary and booster immunization in Japan
On Apr. 19, 2022, Novavax announced that its partner, Takeda, received manufacturing and marketing approval from the Japan…
-
FDA Authorizes Changes to Simplify Use of Bivalent mRNA COVID-19 Vaccines
On Apr. 18, 2022, the U.S. Food and Drug Administration (FDA) amended the emergency use authorizations (EUAs) of…
-
Pfizer and BioNTech data demonstrated high immune response following booster dose of COVID-19 vaccine in children 5 through 11 years of age
On Mar. 14, 2022, Pfizer and BioNTech announced positive results from a Phase 2/3 clinical trial evaluating the…
-
FDA authorized first COVID-19 diagnostic test using breath samples
On Apr. 14, 2022, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the…
-
Merck announced FDA granted breakthrough therapy designation for V116, investigational 21-valent pneumococcal conjugate vaccine, for prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults
On Apr. 14, 2022, Merck announced that V116, the companyﾒs investigational 21-valent pneumococcal conjugate vaccine, had received Breakthrough…
-
Swissmedic granted conditional Marketing Authorization for Novavax COVID-19 vaccine
On Apr. 13, 2022, Novavax announced that Swissmedic had granted Novavax conditional marketing authorization (CMA) for Nuvaxovid COVID-19…
